Zobrazeno 1 - 10
of 49
pro vyhledávání: '"David A Hokey"'
Autor:
Tereza Masonou, David A Hokey, Timothy Lahey, Alice Halliday, Luis C Berrocal-Almanza, Wendy F Wieland-Alter, Robert D Arbeit, Ajit Lalvani, C Fordham von Reyn
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0217091 (2019)
BACKGROUND:DAR-901 is an inactivated whole cell tuberculosis booster vaccine, prepared using a new scalable, broth-grown method from the master cell bank of SRL172, a vaccine previously shown to prevent tuberculosis. This study examined whether DAR-9
Externí odkaz:
https://doaj.org/article/88ddceddb42140d889ed399b458a473e
Autor:
C Fordham von Reyn, Timothy Lahey, Robert D Arbeit, Bernard Landry, Leway Kailani, Lisa V Adams, Brenda C Haynes, Todd Mackenzie, Wendy Wieland-Alter, Ruth I Connor, Sue Tvaroha, David A Hokey, Ann M Ginsberg, Richard Waddell
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0175215 (2017)
Development of a tuberculosis vaccine to boost BCG is a major international health priority. SRL172, an inactivated whole cell booster derived from a non-tuberculous mycobacterium, is the only new vaccine against tuberculosis to have demonstrated eff
Externí odkaz:
https://doaj.org/article/72ed7a4d28b543bb9c08543d05916f7e
Autor:
Sharon Sheehan, Stephanie A Harris, Iman Satti, David A Hokey, Veerabadran Dheenadhayalan, Lisa Stockdale, Zita-Rose Manjaly Thomas, Alice Minhinnick, Morven Wilkie, Samantha Vermaak, Joel Meyer, Matthew K O'Shea, Maria Grazia Pau, Isabella Versteege, Macaya Douoguih, Jenny Hendriks, Jerald Sadoff, Bernard Landry, Paul Moss, Helen McShane
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0141687 (2015)
MVA85A and AERAS-402 are two clinically advanced viral vectored TB vaccine candidates expressing Mycobacterium tuberculosis antigens designed to boost BCG-induced immunity. Clinical trials with candidate malaria vaccines have demonstrated that adenov
Externí odkaz:
https://doaj.org/article/5b7a79c4e6d34056983f405b41737c6f
Autor:
Synne Jenum, Harleen M S Grewal, David A Hokey, John Kenneth, Mario Vaz, Timothy Mark Doherty, Frode Lars Jahnsen, TB Trials Study Group
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e101224 (2014)
BackgroundQuantiFERON-TB Gold In-Tube (QFT) is an IFNγ-release assay used in the diagnosis of Mycobacterium tuberculosis (MTB) infection. The risk of TB progression increases with the magnitude of the MTB-specific IFNγ-response. QFT reversion, also
Externí odkaz:
https://doaj.org/article/1b9b875ee60b4e01b7cd37647e483ff0
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24250 (2011)
Costimulatory molecules play a central role in the development of cellular immunity. Understanding how costimulatory pathways can be directed to positively influence the immune response may be critical for the generation of an effective HIV vaccine.
Externí odkaz:
https://doaj.org/article/77d1fcd4df1a4d00949221dd3f4bd163
Autor:
Sina Salajegheh Tazerji, Phelipe Magalhães Duarte, Parastoo Rahimi, Fatemeh Shahabinejad, Santosh Dhakal, Yashpal Singh Malik, Awad A. Shehata, Juan Lama, Jörn Klein, Muhammad Safdar, Md. Tanvir Rahman, Krzysztof J. Filipiak, Alfonso J. Rodríguez-Morales, Md. Abdus Sobur, Farrokhreza Kabir, Bita Vazir, Leonard Mboera, Marco Caporale, Md. Saiful Islam, John H. Amuasi, Rasha Gharieb, Paola Roncada, Sahar Musaad, Bruno Tilocca, Mohammad Kazem Koohi, Ali Taghipour, Ahmet Sait, Kannan Subbaram, Alireza Jahandideh, Pejman Mortazavi, Mohammad Amin Abedini, David A. Hokey, Unarose Hogan, Mohamed N. F. Shaheen, Ahmed Elaswad, Mahmoud M. Elhaig, Mohamed Fawzy
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-11 (2020)
Abstract COVID-19 caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated in Wuhan (Hubei province, China) during late 2019. It has spread across the globe affecting nearly 21 million people with a toll of 0.75 milli
Externí odkaz:
https://doaj.org/article/1ba4730494244a06bb8b0feb87ba0302
Autor:
Ann M. Ginsberg, Thomas J. Scriba, Mark Hatherill, Carlos A. DiazGranados, William Fulp, Mzwandile Erasmus, Greg Finak, C Study Team, Hennie Geldenhuys, Sanjay Gurunathan, Asma Toefy, Munyaradzi Musvosvi, Linda-Gail Bekker, Muki Shey, Virginie Rozot, Nicole Bilek, David A. Hokey, Frances Rantangee, Lebohang Makhethe, Simbarashe Mabwe, Elisa Nemes
Publikováno v:
Communications Biology
Communications Biology, Vol 3, Iss 1, Pp 1-12 (2020)
Communications Biology, Vol 3, Iss 1, Pp 1-12 (2020)
We characterize the breadth, function and phenotype of innate and adaptive cellular responses in a prevention of Mycobacterium tuberculosis infection trial. Responses are measured by whole blood intracellular cytokine staining at baseline and 70 days
Autor:
Mohamed N. F. Shaheen, Alireza Jahandideh, Marco Caporale, Abdus Sobur, John H Amuasi, Unarose Hogan, Rasha M. A. Gharieb, Saiful Islam, Bruno Tilocca, Pejman Mortazavi, Mahmoud M. Elhaig, Mohammad Abedini, Juan Lama, David A Hokey, B Vazir, F R Kabir, Parastoo Rahimi, Ahmed Elaswad, Phelipe Magalhães Duarte, Sina Salajegheh Tazerji, Krzysztof J. Filipiak, Fatemeh Shahabinejad, Jörn Klein, Alfonso J. Rodriguez-Morales, Ahmet Sait, Paola Roncada, Santosh Dhakal, Mohamed Fawzy, Sahar Musaad, Kannan Subbaram, Muhammad Safdar, Awad A. Shehata, Yashpal Singh Malik, Tanvir Rahman, Ali Taghipour, Leonard E. G. Mboera, Mohammad Kazem Koohi
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-11 (2020)
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-11 (2020)
COVID-19 caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated in Wuhan (Hubei province, China) during late 2019. It has spread across the globe affecting nearly 21 million people with a toll of 0.75 million deaths
Autor:
Wendy Wieland-Alter, Luis C Berrocal-Almanza, Alice Halliday, Tereza Masonou, Ajit Lalvani, C. Fordham von Reyn, Timothy Lahey, Robert D. Arbeit, David A. Hokey
Publikováno v:
Masonou, T, Hokey, D A, Lahey, T, Halliday, A, Berrocal-Almanza, L C, Wieland-Alter, W F, Arbeit, R D, Lalvani, A & von Reyn, C F 2019, ' CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults : A randomized, placebo-controlled trial ', PLoS ONE, vol. 14, no. 5, e0217091 . https://doi.org/10.1371/journal.pone.0217091
PLoS ONE
PLoS ONE, Vol 14, Iss 5, p e0217091 (2019)
PLoS ONE
PLoS ONE, Vol 14, Iss 5, p e0217091 (2019)
Background DAR-901 is an inactivated whole cell tuberculosis booster vaccine, prepared using a new scalable, broth-grown method from the master cell bank of SRL172, a vaccine previously shown to prevent tuberculosis. This study examined whether DAR-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a6039b92de414116bca08f80327bc76
http://hdl.handle.net/10044/1/70427
http://hdl.handle.net/10044/1/70427
Autor:
Elisa, Nemes, Hennie, Geldenhuys, Virginie, Rozot, Kathryn T, Rutkowski, Frances, Ratangee, Nicole, Bilek, Simbarashe, Mabwe, Lebohang, Makhethe, Mzwandile, Erasmus, Asma, Toefy, Humphrey, Mulenga, Willem A, Hanekom, Steven G, Self, Linda-Gail, Bekker, Robert, Ryall, Sanjay, Gurunathan, Carlos A, DiazGranados, Peter, Andersen, Ingrid, Kromann, Thomas, Evans, Ruth D, Ellis, Bernard, Landry, David A, Hokey, Robert, Hopkins, Ann M, Ginsberg, Thomas J, Scriba, Mark, Hatherill, Noncedo, Xoyana
Publikováno v:
The New England Journal of Medicine
Recent Mycobacterium tuberculosis infection confers a predisposition to the development of tuberculosis disease, the leading killer among global infectious diseases. H4:IC31, a candidate subunit vaccine, has shown protection against tuberculosis dise